Dalpiciclib plus letrozole for maintenance after chemo
Part of Cancer, Skin clinical trials.
This trial tests whether a combination of two pills (dalpiciclib and letrozole) can help maintain control of hormone-receptor-positive, HER2-negative breast cancer after initial chemotherapy. It is for people whose cancer has spread or returned and who have not been on an oral CDK4/6 inhibitor before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a type of breast cancer called hormone receptor positive and HER2 negative that has spread to other parts of your body or come back after initial treatment.
- You should be between 18 and 75 years old.
- You must be in good enough health to take care of yourself (a score of 0 or 1 on a standard health scale).
- Your liver and kidneys must be working normally.
- You must agree to use effective birth control during the study.
- You cannot have had treatment with a CDK4/6 inhibitor (like Ibrance, Kisqali, or Verzenio) before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new combination of oral hormone therapy (an aromatase inhibitor) plus a CDK4/6 inhibitor (dalpiciclib) for women with early-stage but locally advanced (Stage II–III) hormone receptor-positive, HER2-negative breast cancer. The goal is to shrink the tumor before surgery, potentially improving outcomes.
This trial studies whether dalpiciclib can slow down or control advanced hormone receptor–positive breast cancer and assess how safe it is. It’s for people whose cancer has come back in a limited way or spread and can’t be fully cured with surgery or radiation.
This trial is testing a combination of three drugs (dalpiciclib, entinostat, and letrozole) for women with early-stage, hormone-receptor-positive, HER2-negative breast cancer. It aims to see if adding these medications before surgery can help shrink the tumor.
This trial tests a combination of three drugs (dalpiciclib, letrozole, and anlotinib) given before surgery to postmenopausal women with stage II or III HR+/HER2- breast cancer. The goal is to see if this neoadjuvant treatment shrinks tumors and improves outcomes.
This trial tests if adding a targeted drug (CDK4/6 inhibitor) to hormone therapy works better than hormone therapy alone for women with a certain type of breast cancer (HR+/HER2-). The study measures the activity of tumor cells (Ki-67) to help decide treatment.
This trial tests a combination of three targeted drugs for a type of advanced breast cancer that is both ER-positive and HER2-positive. The goal is to see if adding these two new drugs to standard hormone therapy can help shrink or control the cancer.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.